Effective sample size for computing prior hyperparameters in Bayesian phase I–II dose-finding
- 1 September 2014
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 11 (6) , 657-666
Abstract
Background: The efficacy–toxicity trade-off based design is a practical Bayesian phase I–II dose-finding methodology. Because the design’s performance is very sensitive to prior hyperparameters and the shape of the target trade-off contour, specifying these two design elements properly is essential. Purpose: The goals are to provide a method that uses elicited mean outcome probabilities to derive a prior that is neither overly informative nor overly disperse, and practical guidelines for specifying the target trade-off contour. Methods: A general algorithm is presented that determines prior hyperparameters using least squares penalized by effective sample size. Guidelines for specifying the trade-off contour are provided. These methods are illustrated by a clinical trial in advanced prostate cancer. A new version of the efficacy–toxicity program is provided for implementation. Results: Together, the algorithm and guidelines provide substantive improvements in the design’s operating characteristics. Limitations: The method requires a substantial number of elicited values and design parameters, and computer simulations are required to obtain an acceptable design. Conclusion: The two key improvements greatly enhance the efficacy–toxicity design’s practical usefulness and are straightforward to implement using the updated computer program. The algorithm for determining prior hyperparameters to ensure a specified level of informativeness is general, and may be applied to models other than that underlying the efficacy–toxicity method.Keywords
This publication has 20 references indexed in Scilit:
- Optimizing the Concentration and Bolus of a Drug Delivered by Continuous InfusionBiometrics, 2011
- Evaluating the Impact of Prior Assumptions in Bayesian BiostatisticsStatistics in Biosciences, 2010
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic AgentsBiometrics, 2009
- Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy as Time-to-Event OutcomesJournal of the Royal Statistical Society Series C: Applied Statistics, 2009
- Determining the Effective Sample Size of a Parametric PriorBiometrics, 2008
- Recent Developments in Adaptive Designs for Phase I/II Dose-Finding StudiesJournal of Biopharmaceutical Statistics, 2007
- Adaptive Dose Selection Using Efficacy-Toxicity Trade-Offs: Illustrations and Practical ConsiderationsJournal of Biopharmaceutical Statistics, 2006
- An adaptive dose-finding design incorporating both toxicity and efficacyStatistics in Medicine, 2005
- A Geometric Approach to Comparing Treatments for Rapidly Fatal DiseasesBiometrics, 2005
- A New Perspective on Priors for Generalized Linear ModelsJournal of the American Statistical Association, 1996